Immunotherapy Archives

News and Trends 19 Apr 2017

UPDATE: Novartis broadens CAR-T onslaught with FDA endorsement

UPDATE (19/04/2017): CTL019 has been granted Breakthrough Designation by the FDA for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Novartis and Kite have been in a tight race to bring the first CAR-T therapy to market: Novartis has staked out acute lymphoblastic leukemia (ALL) while Kite has gone for DLBCL. With this “tacit endorsement,” Novartis is encroaching on […]

April 19, 2017 - 3 minutesmins - By Evelyn Warner

Patrick Baeuerle Successful German Biotech Leader

Interview 17 Apr 2017

Meet One of the Most Successful German Biotech Leaders Ever

Patrick Baeuerle is the German biotech leader I wanted to interview the most (besides Simon Moroney from MorphoSys, who came to our Meetup in Munich last week). Patrick has explored and succeeded in just about every area of life sciences, be it as a highly cited academic researcher, a professor at Freiburg University, head of drug […]

April 17, 2017 - 6 minutesmins - By Philip Hemme

Transgene Pexa Vec Oncolytic Virus Vaccine

News and Trends 13 Apr 2017

French Oncolytic Virus Vaccine for Breast Cancer enters Phase II

After positive results in Phase I, Transgene has started Phase II with Pexa-Vec in combination with chemotherapy to treat breast cancer and sarcoma. After years of financial instability, Transgene is stepping up its game in cancer immunotherapies. Last year, its first Phase III trial and a deal with Merck and Pfizer brought the hopes of investors […]

April 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Heptares AstraZeneka AZD4635 checkpoint inhibitor

News and Trends 5 Apr 2017

Heptares Takes Home €11M for its Next-Generation Checkpoint Inhibitor

Heptares Therapeutics has achieved a new milestone in its immuno-oncology collaboration with AstraZeneca triggering an €11M payment from AstraZeneca. Heptares has announced the wrap-up of its preclinical programme for a new checkpoint inhibitor, AZD4635 that reverses adenosine-mediated T cell suppression and enhances anti-tumor immunity. The British company will now receive an €11M ($12M) milestone payment from AstraZeneca, who obtained exclusive global rights […]

April 5, 2017 - 3 minutesmins - By Melanie De Almeida

C7XeJ78WkAEE Ic 1.jpg large e1490029653662

Interview 20 Mar 2017

Immuno-oncology is Overcrowded – Here is Where Startups Can Succeed

The unprecedented competition in the field represents a daunting challenge for companies trying to break in. A BIO-Europe Panel discussed remaining niches. BIO Europe’s panel on immuno-oncology was perhaps the most popular of the day, as attendees filled the room to hear the thoughts of John Haurum, CEO of F-star; Christophe Quéva, CSO of iTeos; and […]

March 20, 2017 - 3 minutesmins - By Evelyn Warner

David Sourdive Cellectis interview off the shelf cell therapy 1

Interview 16 Mar 2017

“In the Coming Decade, Off-the-Shelf Cell Therapy will Become a Reality”

David Sourdive, co-founder of Cellectis, discusses his pioneering work developing off-the-shelf CAR-T for cancer and the future directions of cell therapy. Last week I had the opportunity to attend the World ADOPT Summit and hear from some of the world leaders in cell therapy. There I met David Sourdive, co-founder and EVP Technical Operations at Cellectis, […]

March 16, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Mar 2017

Researchers Develop New Virus to Selectively Attack Tumor Cells

Researchers from Barcelona have developed a new genetically engineered oncolytic virus, which can selectively infect and kill tumor cells. Eneko Villanueva and colleagues from the IDIBAPS Biomedical Research Institute and the Institute for Research in Biomedicine (IRB Barcelona) have engineered a virus that infects tumor cells without affecting healthy tissues. Their new cancer therapy approach is based […]

March 16, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 16 Mar 2017

UK Immunotherapy Biotech raises Massive Funding in Series C

The UK biotech Cell Medica picked up a massive €69M (£60M) in its recent Series C funding round to advance its cancer immunotherapy programs. Cell Medica is a clinical stage company developing cell-based therapies to treat cancer. With the aim of advancing the clinical development of its immunotherapies, the company was able to raise an impressive […]

March 16, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 21 Feb 2017

New Immunotherapy Candidate receives FDA Fast Track Designation

Cell Medica’s Orphan Drug CMD-003 has received fast track designation by the FDA to advance immunotherapy of patients with Epstein Bar Virus (EBV)-associated malignancies. The FDA’s fast track designation has been designed to facilitate and accelerate the development of drugs which fill a major unmet medical need. It has now been granted to Cell Medica’s lead EBV immunotherapy […]

February 21, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 14 Feb 2017

Suffering from House Dust Mite Allergy? A New Therapy is on its Way

Allergy Therapeutics, a UK-based biotech company, just announced the approval of its clinical trial application in Spain to advance its next-generation house dust mite allergy vaccine into phase I clinical development. The company Allergy Therapeutics is developing immunotherapeutic vaccines for the treatment of allergies and has been quite successful. Their Pollinex Quattro range of vaccines against […]

February 14, 2017 - 2 minutesmins - By Melanie De Almeida

Infographics 13 Feb 2017

Infographic: What’s in Europe’s Immuno-oncology Pipeline?

While some might accuse the field of being over-hyped, immuno-oncology continues to attract attention and investment for its potential to cure cancer. What new therapies are European biotech cooking up? Since the dawn of immuno-oncology broke with checkpoint inhibitors, innovative therapies like Keytruda and Rituxan from big pharma have taken the world by storm. European biotech’s pipeline is […]

February 13, 2017 - 2 minutesmins - By Evelyn Warner

Isogenica Maverick Therapeutics llama antibodies cancer 1

News and Trends 7 Feb 2017

British Synbio’s Llama Antibodies recruited for Cancer T-Cell Therapy

Isogenica has licensed its synthetic llama antibody library to Maverick Therapeutics, which develops cancer T-cell therapies designed to reduce side effects. Isogenica is a synthetic biology company near Cambridge that develops libraries of therapeutic antibodies. The biotech has granted US-based Maverick Therapeutics licenses to its llamdA VHH antibody library for the discovery, development and commercialization of […]

February 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Immunotherapy

UPDATE: Novartis broadens CAR-T onslaught with FDA endorsement

Meet One of the Most Successful German Biotech Leaders Ever

French Oncolytic Virus Vaccine for Breast Cancer enters Phase II

Heptares Takes Home €11M for its Next-Generation Checkpoint Inhibitor

Immuno-oncology is Overcrowded – Here is Where Startups Can Succeed

“In the Coming Decade, Off-the-Shelf Cell Therapy will Become a Reality”

Researchers Develop New Virus to Selectively Attack Tumor Cells

UK Immunotherapy Biotech raises Massive Funding in Series C

New Immunotherapy Candidate receives FDA Fast Track Designation

Suffering from House Dust Mite Allergy? A New Therapy is on its Way

Infographic: What’s in Europe’s Immuno-oncology Pipeline?

British Synbio’s Llama Antibodies recruited for Cancer T-Cell Therapy

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!